Moderna Announces Coronavirus Vaccine With 95.5% Success Rate

Moderna Announces Coronavirus Vaccine With 94.5% Success Rate

Moderna Inc. claims that its COVID-19 vaccine is 94.5% effective—a higher rate than Pfizer’s vaccine.

Biotech company Moderna Inc. announced on November 16 that the coronavirus vaccine it has developed is 94.5% effective, according to NPR.

This information arrives on the heels of a new record number of coronavirus cases. As of November 15, there are more than 11 million confirmed COVID-19 cases in the United States. Johns Hopkins’ COVID-19 tracker reports 166,55 new cases and 1,266 new deaths. This new peak occurs just six days after the U.S. reached 10 million coronavirus cases.

This is the second vaccine of nearly 100% effectiveness to emerge—last week, Pfizer announced its own vaccine with a 90% rate of effectiveness.

Moderna will file for emergency use authorization from the FDA for the vaccine within the next few weeks. The company expects to ship 20 million doses of the vaccine in the United States by the end of this year.

About the Author

Nikki Johnson-Bolden is an Associate Content Editor for Occupational Health & Safety.

Download Center

OH&S Digital Edition

  • OHS Magazine Digital Edition - May 2021

    May 2021

    Featuring:

    • COMBUSTIBLE DUST
      What to Do with Your Dust Hazard Analysis
    • RESPIRATORY PROTECTION
      What's New in Respiratory Protection
    • HAND PROTECTION
      Sustainable Industrial Protection Equipment
    • INDUSTRIAL HYGIENE
      Evaluating Occupational Noise Exposure
    View This Issue